![](https://investorshub.advfn.com/uicon/250952.png?cb=1618145303)
Sunday, December 09, 2012 6:44:15 AM
What I don't understand, probably it has to do with the long waiting for some like me that are in this stock 5,10,15 years, is the uder-estimations.
I have seen posts of 50 potential cancer types to test Bavi with, I know all of you are aware of Bavi's viral potential and Digital imaging, and on top of all that there is potential in many other medical areas where PS is involved reaching from infections to apparently even unsuspected diseases such as Alzheimer.
So we all are aware about the fundamental level at which Bavi is doing it's things, reasons for the wide range of applications.
I also know that most of you know the problems of side effects and healthy tissue damage with chemo/radio treatments and that you can see how Cotara can play a role there.
Finally I have seen posts about other acquisitions of companies with a single product for a single condition, I have seen posts about the 1500 ongoing trials for Avastin, about Avasting being taken of the market by the FDA because of side effects, I've seen posts about the NEW regulation of the FDA for faster approval and different approaches for the approval of totally new drugs, where Bavi and posibly even Cotara certainly qualify.
I have seen observations where one said that for the first time EVER an FDA approval for PIII (Cotara) was seen as a bad thing by some writers, that BPs pipeline's are drying out and that tons of money are being spend to buy or run new pipeline, that don't even come as high as Bavi's knees.
We know that Peregrine's Management had to do it's day job at night during talks, that some like to diminish by saying they could as well be talking with only one BP. We've heard SK say that the partners are still there, they just want to understand the discrepancies before moving on. We've seen tremendously new amounts of Inst. Inv. (Ayer 5+Milj shares), while we had already some big ones. Our daily volume average has never been higher, we are not talking about hundred of thousands, we are talking millions at this moment.
And then to say that Bavi sponsored all that with the market, the ATM and has no creditors and 100% owns all the pipeline and intellectual property so it can freely negotiate and make the best price of it. Very often companies are acquired based on their potential and afterwards that potential is often not what it look like as first. Peregrine is a Biotechnology company and proves the potential of it's claims by clinical trials.
You do not need to be FTM, entdoc or one of the other knowledgeable science posters to see and understand that potential, do you? Most of us here are well aware of it, reasons why we can't be scared away or talked out of our shares anymore by those that use the "momentum" to spread the doom and hit the weak hands. In a way that is good for us because as someone posted we profit from it too because we can increase our positions at prices we would not have expected anymore and of which we know that if we head back to 5+$ it is not going to be a smooth process but a JUMP the next significant announcement.
So what I do not understand is the 25 to 100$ range pps estimates. The few billion $ acquisitions that would be experienced as ok.
Well, for me it is not OK. Call me greedy if you want, but I didn't invest in the Microsoft of Biotechnology, stay with it for 10+ years, build up my position ones I saw that what I suspected was going to succeed, to get 50$ a share!
If Qualcom, who's technology is great but falls into nothing compared to the break-through that Peregrine is making here, could go from 25$ tot 1000$ in a couple of months then Peregrine can too and even do better. With not ONE but a train of announcements it has in the tunnel and given the leverage compared to a wireless-phone chip that it has and the world wide market compared to only one of the US wireless networks types it is in pole position for the race.
The fight for this company will be enormous! I think you all understand that if you where a BP you do not want Peregrine to end up in the hands of your competitors! Just imagine you are Roche and have all that money invested in Avastin which is a multi-billion revenue maker! Do you want a smaller BP to buy Peregrine, do Clinical Trials in no time wipe your candidate of the table, take your revenue and what is even worse ESTABLISH A HARD TO BEAT SOC (Standard of Care)! Do you have ANY idea what it will take to beat a SOC that includes Bavi. You would have to include Bavi or come up with a better drug. A break through like Bavi is not something that will be on the table every 10 years.
Now, many things may be said about management and I may even agree that in the BoD only SK knows about Biotechnology, just assume, but there is one thing I know about those others: They are not sufficiently inexperience or stupid in order not the know the value of their company. By the way, as a rule people even over estimate what they have until it is negotiated to the real value.
So bottom-line, if Peregrine would be sold for let's say 15 Billion, that would be about 120-150$ per share, I would be really disappointed and I would accept that I would have hit the ball dramatically wrong with the slogan:
Peregrine Pharmaceuticals to become the Microsoft of Biotechnology
Peregrine Pharmaceuticals to become the Microsoft of Biotechnology! All In My Opinion. I am not advising anything, nor accusing anyone.
Recent CDMO News
- Avid Bioservices to Report Financial Results for First Quarter of Fiscal Year 2025 After Market Close on September 9, 2024 • GlobeNewswire Inc. • 09/03/2024 08:05:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/29/2024 08:30:10 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 08/28/2024 08:34:04 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 08/28/2024 08:32:18 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 08/28/2024 08:30:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/16/2024 11:50:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/16/2024 11:48:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/15/2024 08:40:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/12/2024 08:30:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:02:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:02:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:01:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:01:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:00:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:00:45 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/11/2024 12:23:26 AM
- Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2024 • GlobeNewswire Inc. • 07/02/2024 08:05:04 PM
- Avid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2024, After Market Close on July 2, 2024 • GlobeNewswire Inc. • 07/01/2024 11:00:21 AM
- Avid Bioservices Earns Committed Badge from EcoVadis for Sustainability Performance • GlobeNewswire Inc. • 05/23/2024 12:05:46 PM
- Avid Bioservices to Participate at Upcoming Investor Conferences • GlobeNewswire Inc. • 05/07/2024 08:05:11 PM
- Avid Bioservices Reports Financial Results for Third Quarter Ended January 31, 2024 • GlobeNewswire Inc. • 04/24/2024 09:25:33 PM
- Avid Bioservices Announces Receipt of Deficiency Notice from Nasdaq Regarding Late Form 10-Q • GlobeNewswire Inc. • 03/20/2024 11:00:10 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 11:30:11 AM
- Avid Bioservices Announces Pricing of Private Placement of Convertible Notes • GlobeNewswire Inc. • 03/07/2024 04:58:48 AM
- Avid Bioservices Announces Proposed Private Placement of Convertible Notes • GlobeNewswire Inc. • 03/06/2024 09:32:07 PM
Simple Stock Loans Announces Unique Solutions For Investors Looking for Alternative Liquidity Amidst Recent Small Cap Rally Sep 6, 2024 9:30 AM
Reliant Coffee Debuts at #271 on the Inc. 5000 List of Fastest Growing Companies - Coffee Service Industry Disruptor Brews Up Exponential Growth Sep 5, 2024 11:51 AM
VAYK Confirms Receiving Revenue from First Airbnb Property with 1.4 Million Annual Revenue Goal • VAYK • Sep 4, 2024 9:34 AM
Mawson Finland Limited Expands Known Mineralized Zones at Rajapalot: New Lens Intercepts 21.75 m at 5.25 g/t Gold & 515 ppm Cobalt • MFL • Sep 4, 2024 9:02 AM
Integrated Ventures Acquires 51% Stake In GetTrim.Com (TM), Telemedicine Platform With Focus On Expansion Into Booming GLP-1 Powered Weight Loss Market • INTV • Sep 4, 2024 8:45 AM
Avant Technologies Announces Strategic Review Process Intended to Maximize Shareholder Value • AVAI • Sep 4, 2024 8:00 AM